[CANF] Can-Fite Biopharma Ltd

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 30.92 M

Exchange: AMEX

The data is delayed by 15 minutes.

 

Price: 2.42 Change: -0.01 (-0.41%)
Ext. hours: Change: 0 (0%)

chart CANF

Refresh chart

Strongest Trends Summary For CANF

CANF is in the medium-term down -36% in 1 month and down -70% in 3 months and up 309% in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Can-Fite BioPharma, Ltd., a clinical-stage biotechnology company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis, as well as completed Phase II study for the treatment of rheumatoid arthritis; completed Phase III study for the treatment of dry eye; completed Phase II study for the treatment of glaucoma; and initiating a Phase II study of CF101 for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of liver cancer; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company is headquartered in Petah-Tikva, Israel.

Fundamental Ratios
Shares Outstanding13.74 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow-4.27 ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities Gross Profit
Net Profit Operating Profit Total Assets Total Current Assets
Total Current Liabilities Total Debt Total Liabilities Total Revenue
Technical Data
High 52 week20.25 Low 52 week1.16 Last close5.15 Last change-9.01%
RSI14.02 Average true range3.86 Beta0.03 Volume40.22 K
Simple moving average 20 days-23.55% Simple moving average 50 days-51.04% Simple moving average 200 days-36.41%
Performance Data
Performance Week-20.65% Performance Month-32.67% Performance Quart-70.01% Performance Half273.19%
Performance Year293.13% Performance Year-to-date-72.75% Volatility daily5.91% Volatility weekly13.22%
Volatility monthly27.09% Volatility yearly93.85% Relative Volume163.54% Average Volume396.1 K
New High New Low

News

2019-06-04 07:00:00 | Can-Fite Participating in One-on-One Partnering Meetings at the BIO International Convention on June 3-6, 2019

2019-06-03 07:00:00 | Findings from Can-Fite’s Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session

2019-05-29 07:00:00 | Can-Fite Reports First Quarter 2019 Financial Results & Provides Clinical Update

2019-05-24 13:46:45 | Secondary Offerings Put A Pause On May's Momentum

2019-05-23 07:00:00 | The Anti-NASH Effect of Namodenoson will be Presented at the International Conference on Fatty Liver in Berlin

2019-05-20 14:06:11 | Can-Fite BioPharma Announces $6 Million Registered Direct Offering

2019-05-20 11:52:36 | Can-Fite Abstract Selected For Liver Conference

2019-05-20 07:00:00 | Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum ILCA

2019-05-06 07:00:00 | Can-Fite Announces Preparation for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Namodenoson

2019-05-01 16:05:00 | Can-Fite Announces ADS Ratio Change

2019-04-15 07:00:00 | Can-Fite Receives $1,000,000 Payment from CKD for Distribution of Namodenoson in South Korea

2019-04-10 07:07:00 | Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson™ Phase II Results at the American Association of Clinical Oncology ASCO Annual Meeting

2019-04-02 09:00:00 | Can-Fite BioPharma Announces $3.2 Million Registered Direct Offering

2019-03-29 16:30:00 | Can-Fite Files Annual Report for the Year Ended December 31, 2018

2019-03-28 07:00:00 | Can-Fite Reports 2018 Financial Results & Provides Clinical Update

2019-03-26 07:00:00 | Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson

2019-03-20 14:15:00 | Four Marijuana Stocks on the Rise on Wednesday

2019-02-27 07:00:00 | Can-Fite to Participate in Bio Asia International Conference on March 5-6, 2019 in Tokyo

2019-02-25 07:00:00 | Can-Fite Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication

2019-02-04 09:30:00 | Watch These 4 Healthcare Stocks Set The Pace On Monday 2/4/19

2019-02-04 07:00:00 | Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis Drug

2019-01-30 09:35:00 | 4 Healthcare Stocks Raising The Bar On Wednesday 1/30/19

2019-01-30 07:00:00 | Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

2019-01-24 07:30:00 | Can-Fite BioPharma CEO Letter to Shareholders

2019-01-18 08:00:00 | Can-Fite BioPharma Announces Registered Direct Offering

2019-01-08 08:00:00 | Can-Fite: Pre-Clinical Data Positions Namodenoson as an anti-Obesity Agent

2019-01-03 08:02:00 | Can-Fite to Participate in the Biotech Showcase™ 2019 and BIO One-on-One Partnering™@ JPM 2019 During the JP Morgan Healthcare Conference

2018-12-10 07:00:00 | Can-Fite Enters Into Collaboration Agreement to Explore Namodenoson’s Anti-NASH Effect With Icahn School of Medicine at Mount Sinai in NYC

2018-11-30 07:00:00 | Can-Fite Reports Third Quarter 2018 Financial Results and Provides Clinical Development Update

2018-11-20 07:00:00 | Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert

2018-10-31 07:00:00 | Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19

2018-10-25 07:00:00 | Can-Fite to Present on its Liver Cancer Drug Namodenoson at the NYC Oncology Investor Conference

2018-10-18 07:00:00 | Can-Fite CEO to present as Expert Speaker on Namodenoson at NASH Summit Europe 2018

2018-09-12 07:00:00 | Can-Fite to Present the Anti-Fibrogenic Effects of Namodenoson at the Hepatic Fibrosis Conference of the American Association for the Study of Liver Diseases AASLD

2018-09-04 07:00:00 | Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected by End of Year

2018-08-31 07:00:00 | Can-Fite Reports Second Quarter 2018 Financial Results and Provides Clinical Update

2018-08-29 07:00:00 | Can-Fite BioPharma Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018

2018-08-21 07:00:00 | Can-Fite Announces Enrollment of First Patient in its Comfort™ Phase III Trial of Piclidenoson in Psoriasis

2018-08-07 09:14:00 | Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China

2018-08-06 05:54:00 | Can-Fite Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical

2018-08-06 05:19:34 | BRIEF-China Medical System Holdings Says It Signed License, Collaboration & Distribution Agreement

2018-07-17 08:56:01 | Benzinga Pro's 5 Stocks To Watch Today

2018-07-17 07:00:00 | Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug

2018-07-02 09:10:15 | Benzinga Pro's 5 Stocks To Watch Today

2018-07-02 07:00:00 | Drugs with Mechanism of Action Utilized by Namodenoson Are Recommended by Leading U.S. Researchers to Be Developed to Combat Liver Cancer

2018-06-19 07:00:00 | Can-Fite Updates on Status of Phase II Advanced Liver Cancer Trial

2018-06-13 08:55:58 | Benzinga Pro's 5 Stocks To Watch Today

2018-06-11 09:32:07 | Benzinga Pro's 5 Stocks To Watch Today

2018-06-11 07:00:00 | Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson

2018-06-01 07:00:00 | Can-Fite Reports First Quarter 2018 Financial Results and Provides Clinical Update